In a study, partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
Investigators conclude that pN1 RCC could be stratified into pN1 and pN2, with pN2 conferring a poor prognosis comparable to that of non-metastatic stage IV pN0 disease.
Cabozantinib can produce responses in patients with advanced clear cell RCC whose disease progressed on first-line checkpoint inhibitor-based therapy, a phase 2 study suggests.